J&J Covid vaccine recipients are better off getting Pfizer or Moderna booster, NIH study suggests
Pfizer-BioNTech Covid-19 vaccines at a senior living facility in Worcester, Pennsylvania, U.S., on Wednesday, Aug. 25, 2021.
Hannah Beier | Bloomberg | Getty Images
Johnson & Johnson Covid-19 vaccine recipients are better off getting a booster shot from Pfizer or Moderna, a highly anticipated U.S. study suggested Wednesday.
The study on “mixing and matching” Covid vaccines included more than 450 adults who have received one of the three regimens currently available in the United States: J&J’s, Moderna’s or Pfizer’s. The study hasn’t yet been peer-reviewed.
Volunteers were divided into groups and received an extra shot of their original vaccine or a booster from a different company.
All the combinations boosted antibody levels higher, though Pfizer’s and Moderna’s boosters appeared to work best. People who received a booster dose of either the Moderna or Pfizer vaccines had a four-fold increase in their antibody responses more often than those who received an extra dose of J&J, according to the study.
The study showed recipients of Moderna or Pfizer’s original vaccines could easily swap third doses; the results were about the same.
This is a developing story. Please check back for updates.
The post J&J Covid vaccine recipients are better off getting Pfizer or Moderna booster, NIH study suggests appeared first on Chop News.
from Chop News https://ift.tt/3lBi18Q
Post a Comment